DOCSLIB.ORG

Folate-Deficient Children on Males

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Folate-Deficient Children on Males Arch Dis Child: first published as 10.1136/adc.47.252.309 on 1 April 1972. Downloaded from Short Reports 309 infection. Since Case 18 failed to respond ade- Summary quately to either arginine alone or arginine with Twenty-six subjects with chromosomal anomalies oestrogen priming, an insulin response test was were studied for responsiveness of plasma growth performed, and she also failed to respond to this. hormone levels to one or more stimuli (arginine, oestrogen priming followed by arginine, and insulin- Discussion induced hypoglycaemia). 4 of these subjects The majority of subjects with chromosomal anoma- required more than one test to demonstrate a lies also have a disorder of growth. Tall stature in positive growth hormone response, and one subject males with multiple X chromosome disorders, and failed to respond to any of 3 tests. It is concluded short stature in subjects with the XO syndrome or that the production of growth hormone in these autosomal aneuploidies are characteristic. No patients is usually normal. adequate explanation for these disorders of growth in subjects with chromosomal anomalies has been REFERENCus advanced. Plasma growth hormone has not been Baker, H. W. G., Best, J. B., and Burger, H. G. (1970). Arginine- infusion test for growth-hormone secretion. Lancet, 2, 1193. studied in these subjects except in a few patients Best, J., Catt, K. J., and Burger, H. C. (1968). Non-specificity of with the XO and XXY syndromes (Frasier, arginine infusion as a test for growth-hormone secretion. Lancet, 2, 124. 1967; Hillman and Colle, 1969; Lundberg andWahl- Frasier, S. D. (1967). The serum growth-hormone response to strom, 1970) in whom the PGH responses were not hypoglycemia in dwarfism. Journal of Pediatrics, 71, 625. Hambert, G. (1966). Males with Positive Sex Chromatin, p. 22. different from those in normal control subjects. Akademiforlaget, Goteborg. In the present study all subjects with anomalies Hillman, D. A., and Colle, E. (1969). Plasma growth hormone and ofthe sex chromosomes had positive PGH responses insulin responses in short children. American Journal of Diseases of Children, 117, 636. (Table). It is of interest that among this group Lundberg, P. O., and Wahlstrom, J. (1970). Hormone levels in the 2 subjects who required more than one test for men with extra Y chromosomes. (Letter to the Editor.) Lancet, 2, 1133. demonstration of a positive PGH response also had Merimee, T. J., Rabinowitz, D., and Fineberg, S. E. (1969). marked growth retardation (more than 2 SD below Arginine-initiated release of human growth hormone. New England Journal of Medicine, 280, 1434. the mean). Moorhead, P. S., Nowell, P. C., Mellman, W. J., Battips, D. M., Among the subjects with autosomal aneuploidy, and Hungerford, D. A. (1960). Chromosome preparations of 3 failed to respond adequately to the initial arginine leukocytes cultured from human peripheral blood. Experimen- tal Cell Research, 20, 613. stimulation test. Two of these (Cases 16 and 24) Parker, M. L., Hammond, J. M., and Daughaday, W. H. (1967). did exhibit adequate PGH responses when the The arginine provocative test: an aid in the diagnosis of hypo- somatotropism. Journal of Clinical Endocrinology and Meta- test was repeated with oestrogen priming. In one bolism, 27, 1129. case (Case 18), a 1696-year-old female who had a Penrose, L. S., and Smith, G. F. (1966). Down's Anomaly, p. 46. age of 3-4 years and mosaicism for a cell Churchill, London; Little Brown, Boston. http://adc.bmj.com/ height Raiti, S., Davis, W. T., and Blizzard, R. M. (1967). A comparison line with possible trisomy D, none of the 3 stimula- of the effects of insulin hypoglycaemia and arginine infusion on tion tests (arginine, arginine with oestrogen priming, release of human growth hormone. Lancet, 2, 1182. insulin) resulted in an adequate response of 5 R. H. A. RuvALCABA,* H. C. THULINE, and V. C. ng/ml above baseline. These results suggest an KELLEY anomaly of growth hormone production in this Rainier School, Buckley, Washington, and Depart- patient which probably contributed to her dwarfism. ment of Pediatrics, University of Washington, The average height of adult patients with Down's Seattle, U.S.A. on October 1, 2021 by guest. Protected copyright. syndrome is approximately 151 cm for males and Washington., 141 cm for females (Penrose and Smith, 1966), *Correspondence to Dr. R. H. A. Ruvalcaba, Rainier School, both values being 3 SD below the mean height for Buckley, Washington 98321, U.S.A. normal subjects. The mean height of 50 adult male subjects with X chromosome anomalies (Klinefelter's syndrome) reported by Hambert Folic Acid Replacement in (1966) was 180-3 cm ± 6 8 cm, which is nearly 1 SD above the mean height for normal adult Folate-deficient Children on males. Since the groups of subjects with Anticonvulsants Klinefelter's and Down's syndromes in our study had normal PGH responses, the characteristic short Reynolds (1967) found that folic acid reversed stature in subjects with Down's syndrome and the the retarding effect of anticonvulsants in 22 out of tall stature in males with multiple X chromosome 26 folate-deficient adult patients, and Neubauet anomalies are probably not related to anomalies of (1970) noted a similar improvement in 28 out of 50 growth hormone production. children. Reynolds (1967) also reported an in- Arch Dis Child: first published as 10.1136/adc.47.252.309 on 1 April 1972. Downloaded from 310 Short Reports crease in fit frequency. Neither study was con- Some children were included in the controlled trolled. Because the increased energy, drive, and trial whose serum folate levels were within the 'speed of cerebration' described by these authors normal adult range for this laboratory (3-10 ng/ml) would benefit children's education, we undertook but the red cell folate levels (Dacie and Lewis, 1968) a control trial of folic acid versus placebo in folate- confirm that they were folate-deficient (Fig.). There deficient children attending a convulsion clinic. was a marked rise in serum and red cell folate levels Simple reaction time and the numbers of hours slept within 9 days of taking folic acid (Fig.). Though were chosen as the objective measurements most there was a significant rise in Hb concentration likely to reflect the changes in behaviour noted by (P <0 03), no variation was found in mean corpus- Reynolds and Neubauer. Fit frequency was also cular volume, serum iron, or serum vitamin B12 recorded. (Matthews, 1962). Patients and Methods We first measured the levels of serum folate (Ball and Giles, 1964), Hb concentration, and mean corpuscular I volume in 39 children (25 boys and 14 girls) who had been taking anticonvulsant drugs for over 3 months. 1,200 We compared their levels with those in 25 children (15 boys and 10 girls) of similar age who were not taking 1,000 anticonvulsants; they were either outpatients or they had been admitted to hospital very recently. -g8T 800 Of the anticonvulsant group, 25 children had serum 4) folate levels below 5 ng/ml. With their parents' permis- 4.- sion, 19 of these entered a trial comparing an 8-week 6600- period of treatment with oral folic acid, 5 mg daily, with a similar period on placebo. The children were used as their own controls and the placebo was given first. o-400 The simple reaction time of those children able to co- operate with the test was estimated on 3 occasions 200- during each treatment. They pressed a button in response to a light signal; we varied the period between 0 signals by hand in a sequence derived from a table of time was measured FIG.-Red cell folate levels during placebo and folic random numbers and the reaction acid administration: shaded area indicates the normal and displayed electronically. The parents kept records adult this of the days on which fits occurred and the number of range for laboratory. hours slept. Haematological data obtained while on http://adc.bmj.com/ placebo were compared with those in the second and Up to 8 weeks after the introduction of folic eighth week on folic acid. acid there was no significant change in the reaction time of the 16 children able to co-operate with the Results test. Similarly there was no significant difference The children taking anticonvulsant treatment in the number of hours slept by the 16 children with had significantly lower serum folate levels than the completed records. Of the 18 children with children of the same age not taking these drugs completed records of days on which fits occurred, (Table), but there was no significant difference in 9 were free of fits during the trial, and the number on October 1, 2021 by guest. Protected copyright. the Hb or mean corpuscular volume (P >0-1). of days on which the other 9 had fits was not affected by folic acid. Two children complained of 'dizziness' while on folic acid but there was no TABLE such complaint while taking the placebo. Comparison of Serum Folate Levels in Children with and without Anticonvulsant Treatment Discussion No. of Cases Our preliminary survey confirms previous obser- Group vations that anticonvulsant therapy is frequently Serum Folate Serum Folate Total associated with low serum folate levels in children <median* > median* (Dahlke and Mertens-Roesler, 1967; Neubauer, Anticonvulsant 25 14 39 1970). No anticonvulsant 7 18 25 The lack of behavioural response to folic acid replacement in this trial is in keeping with the P =*001 (Fisher-Yates 2 x 2 contingency tables). *Median serum folate level (all children) = 5 ng/ml. findings of 3 double-blind trials in adults (Grant Arch Dis Child: first published as 10.1136/adc.47.252.309 on 1 April 1972.
Load more

Recommended publications
  • Causes of Short Stature Author Alan D Rogol, MD, Phd Section Editors
    Causes of short stature Author Alan D Rogol, MD, PhD Section Editors Peter J Snyder, MD Mitchell Geffner, MD Deputy Editor Alison G Hoppin, MD Contributor disclosures All topics are updated as new evidence becomes available and our peer review process is complete. Literature review current through: Mar 2016. | This topic last updated: Aug 13, 2015. INTRODUCTION — Short stature is a term applied to a child whose height is 2 standard deviations (SD) or more below the mean for children of that sex and chronologic age (and ideally of the same racial-ethnic group). This corresponds to a height that is below the 2.3rd percentile. Short stature may be either a variant of normal growth or caused by a disease. The most common causes of short stature beyond the first year or two of life are familial (genetic) short stature and delayed (constitutional) growth, which are normal non-pathologic variants of growth. The goal of the evaluation of a child with short stature is to identify the subset of children with pathologic causes (such as Turner syndrome, inflammatory bowel disease or other underlying systemic disease, or growth hormone deficiency). The evaluation also assesses the severity of the short stature and likely growth trajectory, to facilitate decisions about intervention, if appropriate. This topic will review the main causes of short stature. The diagnostic approach to children with short stature is discussed separately. (See "Diagnostic approach to children and adolescents with short stature".) NORMAL VARIANTS OF GROWTH Familial short stature — Familial or genetic short stature is most often a normal variant, termed familial or genetic short stature (figure 1).
    [Show full text]
  • Turner Syndrome (TS) Is a Genetic Disease That Affects About Physical Signs of TS May Include: 1 in Every 2,500 Female Live Births
    Notes: A Guide for Caregivers For easily accessible answers, education, and support, visit Nutropin.com or call 1-866-NUTROPIN (1-866-688-7674). 18 19 of patients with Your healthcare team is your primary source Turner Syndrome of information about your child’s treatment. Please see the accompanying full Prescribing Information, including Instructions for Use, and additional Important Safety Information througout and on pages 16-18. Models used for illustrative purposes only. Nutropin, Nutropin AQ, and NuSpin are registered trademarks, Nutropin GPS is a trademark, and NuAccess is a service mark of Genentech, Inc. © 2020 Genentech USA, Inc., 1 DNA Way, So. San Francisco, CA 94080 M-US-00005837(v1.0) 06/20 FPO Understanding Turner Syndrome What is Turner Syndrome? Turner Syndrome (TS) is a genetic disease that affects about Physical signs of TS may include: 1 in every 2,500 female live births. TS occurs when one • Short stature of a girl’s two X chromosomes is absent or incomplete. • Webbing of the neck Chromosomes are found in all cells of the human body. They contain the genes that determine the characteristics of a • Low-set, rotated ears person such as the color of hair or eyes. Every person has • Arms that turn out slightly at the elbows 22 pairs of chromosomes containing these characteristics, • Low hairline at the back of the head and one pair of sex chromosomes. • A high, arched palate in the mouth Normally cells in a female’s body contain two “X” chromosomes Biological signs of TS may include: (Fig. 1). • Underdevelopment of the ovaries In girls with TS, part or • Not reaching sexual maturity or starting all of one X chromosome a menstrual period (Fig.
    [Show full text]
  • Current Dosing of Growth Hormone in Children with Growth Hormone Deficiency: How Physiologic?
    Current Dosing of Growth Hormone in Children With Growth Hormone Deficiency: How Physiologic? Margaret H. MacGillivray, MD*; Sandra L. Blethen, MD, PhD‡; John G. Buchlis, MD*; Richard R. Clopper, ScD*; David E. Sandberg, PhD*; and Thomas A. Conboy, MS* ABSTRACT. The current doses of recombinant growth ARE THE APPROVED RECOMBINANT HUMAN GH hormone (rGH) are two to three times those used in the DOSING REGIMENS PHYSIOLOGIC? pituitary growth hormone era. These rGH doses (0.025 to A standard method for determining whether hor- 0.043 mg/kg/d) are similar to or moderately greater than mone replacement is physiologic is to compare the the physiologic requirements. Growth velocity and dose of hormone administered with the amount of height gains have been shown to be greater with 0.05 that hormone produced daily in healthy persons. For mg/kg/d of rGH than with 0.025 mg/kg/d. Larger doses of human GH, this is not an easy task because of its GH and early initiation of treatment result in greater short half-life, multicompartmental distribution, and heights at the onset of puberty and greater adult heights. Earlier onset of puberty and more rapid maturation, as episodic pulsatile pattern of secretion. In addition, indicated by bone age, were not observed in children GH has a variable secretion profile that is influenced who were given 0.18 to 0.3 mg/kg/wk of rGH. The fre- by age, diurnal rhythm, sleep, stress, nutrition, body quency of adverse events is very low, but diligent sur- weight, and sex hormones. One approach to calcu- veillance of all children who are treated with rGH is lating daily levels of endogenously produced GH essential.
    [Show full text]
  • Obese Children and Adolescents: a Risk Group for Low Vitamin B12
    ARTICLE Obese Children and Adolescents A Risk Group for Low Vitamin B12 Concentration Orit Pinhas-Hamiel, MD; Noa Doron-Panush, RD; Brian Reichman, MD; Dorit Nitzan-Kaluski, MD, MPH, RD; Shlomit Shalitin, MD; Liat Geva-Lerner, MD Objective: To assess whether overweight children and Results: Median concentration of serum B12 in normal- adolescents are at an increased risk for vitamin B12 deficiency. weight children was 530 pg/mL and in obese children, Ͻ 400 pg/mL (P .001). Low B12 concentrations were noted Design: Prospective descriptive study. in 10.4% of the obese children compared with only 2.2% Ͻ of the normal weight group (P .001). Vitamin B12 defi- Setting: Two pediatric endocrine centers in Israel. ciency was noted in 12 children, 8 (4.9%) of the obese subjects and 4 (1.8%) of the normal weight group (P=.08). Participants: Three hundred ninety-two children and After we adjusted for age and sex, obesity was associ- adolescents were divided into 2 groups as follows: the ated with a 4.3-fold risk for low serum B12, and each unit normal-weight group had body mass indexes, calcu- increase in body mass index standard deviation score re- lated as weight in kilograms divided by height in meters sulted in an increased risk of 1.24 (95% confidence in- squared, under the 95th percentile (Ͻ1.645 standard de- terval, 0.99-1.56). viation scores; n=228); the obese group had body mass indexes equal to or above the 95th percentile (Ն1.645 standard deviation scores; n=164). Conclusions: Obesity in children and adolescents was associated with an increased risk of low vitamin B12 con- Intervention: We measured vitamin B12 concentra- centration.
    [Show full text]
  • Assessing the Intergenerational Linkage Between Short Maternal Stature and Under-Five Stunting and Wasting in Bangladesh
    nutrients Article Assessing the Intergenerational Linkage between Short Maternal Stature and Under-Five Stunting and Wasting in Bangladesh Wajiha Khatun 1,*, Sabrina Rasheed 2 , Ashraful Alam 1 , Tanvir M. Huda 1 and Michael J. Dibley 1 1 Sydney School of Public Health, Edward Ford Building (A27), University of Sydney, Sydney, NSW 2006, Australia 2 International Centre for Diarrhoeal Disease Research Bangladesh, Mohakhali, Dhaka 1212, Bangladesh * Correspondence: [email protected]; Tel.: +61-88-017-4608-6278 Received: 30 May 2019; Accepted: 13 July 2019; Published: 7 August 2019 Abstract: Short maternal stature is identified as a strong predictor of offspring undernutrition in low and middle-income countries. However, there is limited information to confirm an intergenerational link between maternal and under-five undernutrition in Bangladesh. Therefore, this study aimed to assess the association between short maternal stature and offspring stunting and wasting in Bangladesh. For analysis, this study pooled the data from four rounds of Bangladesh Demographic and Health Surveys (BDHS) 2004, 2007, 2011, and 2014 that included about 28,123 singleton children aged 0–59 months born to mothers aged 15–49 years. Data on sociodemographic factors, birth history, and anthropometry were analyzed using STATA 14.2 to perform a multivariable model using ‘Modified Poisson Regression’ with step-wise backward elimination procedures. In an adjusted model, every 1 cm increase in maternal height significantly reduced the risk of stunting (relative risks (RR) = 0.960; 95% confidence interval (CI): 0.957, 0.962) and wasting (RR = 0.986; 95% CI: 0.980, 0.992). The children of the short statured mothers (<145 cm) had about two times greater risk of stunting and three times the risk of severe stunting, 1.28 times the risk of wasting, and 1.43 times the risk of severe wasting (RR = 1.43; 95% CI: 1.11, 1.83) than the tall mothers ( 155 cm).
    [Show full text]
  • Effects of Growth Hormone Treatment on Body Proportions and Final Height Among Small Children with X-Linked Hypophosphatemic Rickets
    Effects of Growth Hormone Treatment on Body Proportions and Final Height Among Small Children With X-Linked Hypophosphatemic Rickets Dieter Haffner, MD*; Richard Nissel, MD*; Elke Wu¨hl, MD‡; and Otto Mehls, MD‡ ABSTRACT. Background. X-linked hypophosphatemic in the PHEX gene, encoding a membrane-bound en- rickets (XLH) is characterized by rickets, disproportion- dopeptidase. PHEX is expressed in bones and teeth ate short stature, and impaired renal phosphate reabsorp- but not in kidney, and efforts are underway to elu- tion and vitamin D metabolism. Despite oral phosphate cidate how PHEX function relates to the mutant phe- and vitamin D treatment, most children with XLH dem- notype.2 onstrate reduced adult height. Pharmacologic treatment consists of oral phos- Objective. To determine the beneficial effects of re- combinant human growth hormone (rhGH) therapy on phate supplementation and calcitriol administration. body proportions and adult height among patients with Although this therapy usually leads to an improve- XLH. ment of rickets, the effects on longitudinal growth Methods. Three initially prepubertal short children are often disappointing.3 Despite adequate phos- (age, 9.4–12.9 years) with XLH were treated with rhGH phate and calcitriol treatment, most previous studies for 3.1 to 6.3 years until adult height was attained. reported reduced adult height among children with Results. rhGH treatment led to sustained increases in XLH.4–7 In addition, children with XLH present with standardized height for all children. The median adult disproportionate growth, ie, relatively preserved height was 0.9 SD (range: 0.5–1.3 SD) greater than that at trunk growth but severely diminished leg growth.8 the initiation of rhGH treatment and exceeded the pre- Previous studies demonstrated that treatment with dicted adult height by 6.2 cm (range: 5.3–9.8 cm).
    [Show full text]
  • Pathogenesis and Diagnostic Criteria for Rickets and Osteomalacia
    Endocrine Journal 2015, 62 (8), 665-671 OPINION Pathogenesis and diagnostic criteria for rickets and osteomalacia —Proposal by an expert panel supported by Ministry of Health, Labour and Welfare, Japan, The Japanese Society for Bone and Mineral Research and The Japan Endocrine Society Seiji Fukumoto1), Keiichi Ozono2), Toshimi Michigami3), Masanori Minagawa4), Ryo Okazaki5), Toshitsugu Sugimoto6), Yasuhiro Takeuchi7) and Toshio Matsumoto1) 1)Fujii Memorial Institute of Medical Sciences, Tokushima University, Tokushima 770-8503, Japan 2)Department of Pediatrics, Osaka University Graduate School of Medicine, Suita 565-0871, Japan 3)Department of Bone and Mineral Research, Research Institute, Osaka Medical Center for Maternal and Child Health, Izumi 594-1101, Japan 4)Department of Endocrinology, Chiba Children’s Hospital, Chiba 266-0007, Japan 5)Third Department of Medicine, Teikyo University Chiba Medical Center, Ichihara 299-0111, Japan 6)Internal Medicine 1, Shimane University Faculty of Medicine, Izumo 693-8501, Japan 7)Division of Endocrinology, Toranomon Hospital Endocrine Center, Tokyo 105-8470, Japan Abstract. Rickets and osteomalacia are diseases characterized by impaired mineralization of bone matrix. Recent investigations revealed that the causes for rickets and osteomalacia are quite variable. While these diseases can severely impair the quality of life of the affected patients, rickets and osteomalacia can be completely cured or at least respond to treatment when properly diagnosed and treated according to the specific causes. On the other hand, there are no standard criteria to diagnose rickets or osteomalacia nationally and internationally. Therefore, we summarize the definition and pathogenesis of rickets and osteomalacia, and propose the diagnostic criteria and a flowchart for the differential diagnosis of various causes for these diseases.
    [Show full text]
  • Short Stature in Renal Disease
    Pediat. Res. 7: 978-982 (1973) A Review: Short Stature in Renal Disease GUNNAR B. STICKLER1141 AND BARRY J. BERGEN Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA Introduction and of CO2 content as a measure of acid-base buffer. Urea in blood is not as precise a measure of renal Factors contributing to short stature in children with function as is serum creatinine or creatinine clearance, renal disease have been investigated by several groups and serum pH is a more reliable indicator of the acid- [1, 2, 10, 13]. Acidosis and chronic malnutrition were base balance than is the CO content. However, these believed to be among the most important causes of the 2 less reliable indicators were the only ones available in growth failure. A critical discussion of the contribut- retrospect. ing causes has been presented by Bergstrom and co- The alkaline phosphatase is uniformly recorded in workers [1], international units per liter, yet until 1956 it was ex- Previous studies, while mentioning clinically evident pressed in Bodansky units (the correction factor to renal rickets as a cause of growth failure, failed to note international units per liter is 17), and from 1956-1966, the possibility that subtle impairment of bone metabo- in King-Armstrong units (correction factor to interna- lism also may be an important factor which contri- tional units per liter is 7.08). butes to growth failure in renal disease. The heights of the patients were compared with nor- We wish to point out that renal rickets may be the mal values for height established by Reed and Stuart most important factor for short stature in renal dis- [8].
    [Show full text]
  • Pediatric Photosensitivity Disorders Dr
    FAST FACTS FOR BOARD REVIEW Series Editor: William W. Huang,MD,MPH W. Series Editor:William Swetha N.Pathak,MD;JacquelineDeLuca,MD Pediatric PhotosensitivityDisorders Table 1. Pediatric Photosensitivity Disorders Disease Pathophysiology Clinical Features Management/Prognosis Other/Pearls Actinic prurigo Strong association Pruritic crusted papules Phototesting: lesions Native Americans, (hydroa aestivale, with HLA-DR4 and nodules in both provoked by UVA or UVB; especially mestizos; Hutchinson (HLA-DRB1*0401/0407); sun-exposed and less spontaneous resolution hardening does not summer prurigo) may be a persistent frequently nonexposed may occur during late occur; histopathology: variant of PMLE sites (ie, buttocks); heal adolescence; may follow dermal perivascular (delayed-type with scarring; mucosal a chronic course that mononuclear cell hypersensitivity) and conjunctival persists in adulthood; infiltrate, lacks papillary from UVA or UVB involvement, with cheilitis photoprotection; topical dermal edema, can see often an initial or only corticosteroids and lymphoid follicles feature; worse in summer topical tacrolimus; from lip biopsies; but can extend to winter NB-UVB or PUVA; occurs hours to cyclosporine or days following azathioprine; thalidomide sun exposure (treatment of choice) for (vs solar urticaria) resistant disease noconflictofinterest. The authorsreport Long Beach,California. Center, LaserSkinCare DeLucaisfrom Dr. North Carolina. Winston-Salem, University, Forest Wake Pathakisfrom Dr. Bloom syndrome AR; BLM (encodes Malar telangiectatic
    [Show full text]
  • A Case of Short Stature and Severe Osteoporosis in a Young Man with Oculocutaneous Albinism: Syndrome Or Coincidence?
    Open Access Case Report DOI: 10.7759/cureus.7817 A Case of Short Stature and Severe Osteoporosis in a Young Man with Oculocutaneous Albinism: Syndrome or Coincidence? Samson O. Oyibo 1 1. Internal Medicine, Peterborough City Hospital, Peterborough, GBR Corresponding author: Samson O. Oyibo, [email protected] Abstract Oculocutaneous albinism (OCA) is a rare autosomal recessive congenital condition characterized by reduced or absent production of the pigment melanin by melanocytes. The affected individuals have increased susceptibility to sunburn and skin cancers. Osteoporosis is a disease entity characterized by the progressive loss of bone mineral density and the deterioration of bone micro-architecture, leading to an increased risk of developing low-trauma fractures. There are many causes of osteoporosis, ranging from primary to secondary causes. Short stature is defined as height less than two standard deviations below the age-specific and gender-specific mean (less than the 2.5th percentile). There have been rare case reports of individuals with OCA having associated osteoporosis or low bone mineral density and short stature. These cases have also been associated with severe skeletal, neurological, and psychomotor disabilities. This paper presents a case of a young man with OCA and short stature who sustained a low-trauma intertrochanteric fracture to his femur bone and was subsequently diagnosed to have clinically significant osteoporosis. This case report while attempting to review the literature also emphasizes the importance
    [Show full text]
  • Growth Hormone Deficiency and Other Indications for Growth Hormone Therapy – Child and Adolescent
    TUE Physician Guidelines Medical Information to Support the Decisions of TUECs GROWTH HORMONE DEFICIENCY AND OTHER INDICATIONS FOR GROWTH HORMONE THERAPY – CHILD AND ADOLESCENT I. MEDICAL CONDITION Growth Hormone Deficiency and other indications for growth hormone therapy (child/adolescent) II. DIAGNOSIS A. Medical History Growth hormone deficiency (GHD) is a result of dysfunction of the hypothalamic- pituitary axis either at the hypothalamic or pituitary levels. The prevalence of GHD is estimated between 1:4000 and 1:10,000. GHD may be present in combination with other pituitary deficiencies, e.g. multiple pituitary hormone deficiency (MPHD) or as an isolated deficiency. Short stature, height more than 2 SD below the population mean, may represent GHD. Low birth weight, hypothyroidism, constitutional delay in growth puberty, celiac disease, inflammatory bowel disease, juvenile arthritis or other chronic systemic diseases as well as dysmorphic phenotypes such as Turner’s syndrome and genetic diagnoses such as Noonan’s syndrome and GH insensitivity syndrome must be considered when evaluating a child/adolescent for GHD. Pituitary tumors, cranial surgery or radiation, head trauma or CNS infections may also result in GHD. Idiopathic short stature (ISS) is defined as height below -2 SD score (SDS) without any concomitant condition or disease that could cause decreased growth (ISS is an acceptable indication for treatment with Growth Hormone in some but not all countries). Failure to treat children with GHD can result in significant physical, psychological and social consequences. Since not all children with GHD will require continued treatment into adulthood, the transition period is very important. The transition period can be defined as beginning in late puberty the time when near adult height has been attained, and ending with full adult maturation (6-7 years after achievement of adult height).
    [Show full text]
  • Short Stature with Pigmentation
    Arch Dis Child: first published as 10.1136/adc.52.8.664 on 1 August 1977. Downloaded from 664 Short reports Summary average in intelligence but not severely subnormal; the skin showed excessive brown pigmentation which A 22-month-old girl with cystinotic rickets was given was not racial-2 were of southern English descent 1 fig 1 ,25-dihydroxycholecalciferol (1,25-DHCC) and 2 Jewish. Pigmentation increased on exposure to daily in addition to standard treatment. Her rickets light. One was an only child, each of the others had healed and linear growth rate appeared to increase. one healthy sib of normal size and colouring; the It is suggested that the effect of 1,25-DHCC and its parents were healthy and not consanguineous. In metabolically active analogues on cystinotic rickets each case pregnancy, birth, and neonatal state were should be further studied. normal; the babies were not small at birth, their weight being in the range 2950-3450 g. Other We are grateful to Dr. R. H. Wilkinson for bio- features are indicated in the Table. chemical help, to Mr. A. J. Bron for the slit-lamp examinations, and to Dr. J. G. G. Ledingham for advice, and also to Leo Laboratories and Roche Table Features of 4 patients with short stature and Products Ltd. for supplies of vitamin D metabolites. pigmentation References Cases Balsan, S., and Garabedian, M. (1972). 25-hydroxycholecal- 1 2 3 4 ciferol. A comparative study in deficiency rickets and different types of resistant rickets. Journal of Clinical Sex F F F M Investigation, 51, 749-759.
    [Show full text]